Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 06, 2015 5:55 AM ET

Healthcare Equipment and Supplies

Company Overview of Bioness Inc.

Company Overview

Bioness Inc. designs, develops, and distributes medical devices for people with stroke, multiple sclerosis, traumatic brain injury, cerebral palsy, and spinal cord injury. It offers L300, a foot drop system for people with various neurological conditions; L300 Plus for foot drop and thigh weakness, which delivers programmed, low-level electrical stimulation to activate the nerves controlling the muscles of the leg; H200, a wireless hand rehabilitation system for reaching, grasping, opening, and closing the hand; and StimRouter, an implantable neuromodulation device designed to treat intractable pain of peripheral nerve origin. The company also offers StimRouter, an implantable neuromodulatio...

25103 Rye Canyon Loop

Valencia, CA 91355

United States

Founded in 2004

Phone:

661-362-4850

Fax:

877-362-4855

Key Executives for Bioness Inc.

Chief Executive Officer and President
Founder and Chairman
Age: 89
Chief Medical Officer
Compensation as of Fiscal Year 2015.

Bioness Inc. Key Developments

Bioness Inc. Announces the Commercial Availability of StimRouter Neuromodulation System at International Neuromodulation Society World Congress

On June 8, 2015, at the International Neuromodulation Society 12th World Congress, Bioness Inc. announced the commercial availability of StimRouter, an implantable neuromodulation device to treat chronic, intractable pain of peripheral nerve origin as an adjunct to other modes of therapy. StimRouter received clearance from the United States Food and Drug Administration (FDA) in February and is the only implantable neuromodulation device indicated to treat chronic pain of peripheral nerve origin. StimRouter is cleared by the FDA to treat chronic pain of peripheral nerve origin. StimRouter is a minimally invasive neuromodulation medical device consisting of an implanted lead, external pulse transmitter (EPT) and conductive electrode, controlled by a small, hand-held wireless control unit. Electrical signals are transmitted transdermally from the EPT through the electrode, down the lead to the target nerve. Each system is programmed at the direction of the physician to meet patient requirements.

Bioness, Inc. Announces Strategic Business Partnership with the American Physical Therapy Association

Bioness Inc. announced that it has been named as a Strategic Business Partner by the American Physical Therapy Association (APTA). Bioness joins a select roster of other companies from the therapeutic device and medical device and services industries that work with APTA to promote evidence-based innovations and expand access to therapy. This partnership is a unique opportunity for Bioness to generate awareness and offer rehabilitation solutions to the 76,000 well-informed and influential current APTA members.

Bioness Inc. Initiates Pilot Study of StimRouter Neuromodulation System for Overactive Bladder

Bioness Inc. announced that four (4) patients have successfully been implanted with the StimRouter Neuromodulation System, for an ongoing Canadian pilot study to evaluate device use in the treatment of overactive bladder symptoms. The StimRouter is already FDA cleared as a treatment for chronic, intractable pain of peripheral nerve origin. Now, this minimally invasive technology is being studied as an alternative treatment for the 35 million people in the United States who suffer from overactive bladder symptoms and the 10 million who receive treatment for it, which contributes $66 billion in annual cost to the U.S. healthcare system. In the pilot study, subjects with documented refractory overactive bladder will receive tibial nerve stimulation via the StimRouter implantable lead and external pulse transmitter. The subjects will manage their treatment at home in accordance with the defined protocol, with periodic in-clinic outcome visits. The device is equipped with a feature to track usage and compliance during the 6-month trial. While the StimRouter has demonstrated efficacy in relieving peripheral nerve pain, the technology has the potential to be leveraged for even more applications.

Similar Private Companies By Industry

Company Name Region
ELENZA, Inc. United States
BioAssay Works, LLC United States
EchoCath, Inc. United States
SiMatrix, Inc. United States
MediSys Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Bioness Inc., please visit www.bioness.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.